Related Experiment Video
Updated: Feb 23, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
16.3K
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel
Yi-Long Wu1, Chang-Li Wang2, Yan Sun3
1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
ESMO Open
|August 30, 2017
Summary
Liquid biopsy offers promising precision medicine for lung cancer. Experts reached six consensuses to address challenges in its clinical and research application, guiding its use for better patient outcomes.
Area of Science:
- Oncology
- Genetics
- Translational Medicine
Background:
- Lung cancer diagnosis and treatment are advancing with precision medicine.
- Liquid biopsy is a minimally invasive technique for genetic profiling and monitoring in lung cancer.
- Clinical translation of liquid biopsy faces challenges in technique, standardization, data analysis, and cost.
Purpose of the Study:
- To discuss and address the challenges in translating liquid biopsy for precision medicine in lung cancer.
- To establish expert consensus on the clinical and research application of liquid biopsy.
Main Methods:
- A trilateral forum was organized at the 13th Chinese Lung Cancer Summit.
- The forum involved oncologists, clinicians, clinical researchers, and industry experts.
- Discussions focused on controversies and challenges in liquid biopsy implementation.
Main Results:
- Six expert consensuses were reached during the forum.
- These consensuses provide guidance for the clinical and research use of liquid biopsy.
- The aim is to facilitate precision medicine in lung cancer management.
Conclusions:
- Expert consensus provides a framework for overcoming liquid biopsy implementation barriers.
- Standardized use of liquid biopsy will advance precision medicine in lung cancer.
- These guidelines will aid both clinical practice and research endeavors.
